Lefamulin (Xenleta™) is a compound that interferes with bacteria’s ability to make protein, which is required for bacteria to grow. It is available in both oral and intravenous (IV) formulations. Lefamulin is FDA-approved for the treatment of adults with community-acquired bacterial pneumonia (CABP). It is currently being studied for its safety and pharmacokinetics in fighting infections in people with CF. 

Status

A phase 1 study to test the safety and pharmacokinetics of lefamulin in adults with CF is currently underway.

Sponsor

This program is sponsored by Nabriva Therapeutics. The program is being conducted within the Therapeutics Development Network.